Black Diamond Therapeutics raises ~$71.6M in public offering of 15M shares at $5.00/share

Black Diamond Therapeutics, Inc.

Underwritten public offering of 15,000,000 shares at $5.00/share; net proceeds ~$71.6M.
Underwriters have 30-day option to buy up to 2,250,000 additional shares (full exercise net ~$82.4M).
Proceeds to advance clinical pipeline including BDTX-1535 for non-small cell lung cancer and for working capital.
Underwriting agreement with Piper Sandler & Co.; officers/directors subject to 60-day lock-up.
Offering expected to close July 5, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Black Diamond Therapeutics, Inc. entered into Underwriting Agreement with Piper Sandler & Co., as representative of the several underwriters valued at approximately $71.6 million (effective 2023-06-29).

Action: entry
Agreement: underwriting
Counterparty: Piper Sandler & Co., as representative of the several underwriters
Value: approximately $71.6 million
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, Black Diamond Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the several underwriters named in Schedule 1 thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 15,000,000 shares (the “Shares”) of common stock

View on SEC.gov

Browse all material agreements →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-077061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.